Long-Term Safety and Efficacy Study of Deucravacitinib in Participants With Systemic Lupus Erythematosus
Recruiting
Bristol-Myers Squibb
Phase 2
2019-03-26
The main objective of the trial is to characterize the long-term safety and tolerability of
BMS-986165 in subjects with Systemic Lupus Erythematosus (SLE).
Safety and Efficacy of Deucravacitinib in Participants With Moderate to Severe Ulcerative Colitis
Active, not recruiting
Bristol-Myers Squibb
Phase 2
2019-07-01
The purpose of this study is to assess the safety and efficacy of oral deucravacitinib in
participants with moderate to severe ulcerative colitis (UC).
Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis
Recruiting
Bristol-Myers Squibb
Phase 3
2019-08-12
The main purpose of this study is to characterize the long-term safety and efficacy of the
drug Deucravacitinib (BMS-986165) in patients who have been previously enrolled in an
applicable Phase 3 psoriasis study.
A Study to Evaluate the Drug Levels of BMS-986165 When Taken as Various Solid Tablet Prototypes by Healthy Participants
Completed
Bristol-Myers Squibb
Phase 1
2020-09-10
The purpose of this study is to evaluate the drug levels of BMS-986165 in when taken by mouth
as various solid tablet prototypes, by healthy participants.
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor
Recruiting
Bristol-Myers Squibb
Phase 3
2021-07-15
The purpose of this study is to evaluate the safety and efficacy of deucravacitinib versus
placebo for the treatment of participants with active PsA who are naïve to biologic disease
modifying antirheumatic drugs or had previously received TNFα inhibitor treatment.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
